Mak683 clinical trial
Web– MAK683 at various doses and dosing regimens showed an ORR of 13% (95% CI: 3.6–29.8) and a DCR of 29% (95% CI: 14.2–48.0). • The reduction of trimethylated … WebClinical Trial Centre, Department of Clinical Oncology, Hong Kong SAR; 5IRCCS National Cancer Institute of Milan Foundation, Milan, Italy; ... MAK683 80 mg BID MAK683 120 mg BID MAK683 150 mg BID MAK683 300 mg BID 4 10 16 17 Patient. Poster presented at the 2024 ASH Annual Meeting; December 11–14, 2024, Atlanta, GA.
Mak683 clinical trial
Did you know?
WebMar 30, 2024 · Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies Ying Huang , … WebMar 23, 2024 · Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), are associated with several tumor types. EZH2 inhibitor, EPZ-6438 (tazemetostat), demonstrated clinical efficacy in patients with acceptable safety profile as monotherapy. EED, a …
WebSep 2, 2016 · Detailed Description. The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial is to evaluate the anti-tumor activity of MAK683. Phase II part will not be opened. WebDetailed Description The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial will be to evaluate the anti-tumor activity of MAK683. Trial Arms Eligibility Criteria
WebEU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the Clinical Trials ... A phase I/II, … WebSep 2, 2016 · Drug: MAK683 Detailed Description The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) …
WebMar 30, 2024 · MAK683 (EED226) Selective EED inhibitor Phase I/II [113] In conclusion, some inhibitors targeting EZH2 have achieved some success, but most anti-tumor studies of EZH2 inhibitors are still in the...
WebMAK683 ( N - ( (5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8- (2-methylpyridin-3-yl)- [1,2,4]triazolo [4,3- c ]pyrimidin-5-amine) is a potent and orally bioavailable EED inhibitor … majestic hydro blue mountainsWebSep 21, 2024 · Clinical trials with numerous CMP inhibitors are also currently in progress to evaluate the therapeutic potential of epigenetic inhibitors. In this review, we aim to provide a summary of genetic mutations in epigenetic genes and a review of CMP inhibitors suitable for preclinical studies or currently in clinical trials. ... MAK683, is currently ... majestic hydrotest calgaryWebThe purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial is to evaluate the anti-tumor activity of MAK683. Phase II part will not be opened. Arms and Interventions majestic in a sentencemajestic huntington indianaWebThe purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. … majestic ilkley openingWebSep 2, 2016 · Full Title of Study: “A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies ... Participating in This Clinical Trial Inclusion Criteria 1. Eastern Cooperative Oncology Group (ECOG): 0 to 2 2. Relapsed or refractory diffuse large B cell lymphoma with measurable disease as determined by Non-Hodgkin's ... majestic ilkley hoursWebNov 23, 2024 · MAK683 is a specific oral inhibitor that impairs EED binding to H3K27me3. This is a Phase I/II study of MAK683 in adult patients with advanced malignancies for … majestic images photography